The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

Ip MS. Update on the current treatment of diabetic retinopathy. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.

DR was graded according to early Treatment Diabetic Retinopathy (ETDRS) criteria. Results: Of 199 subjects, 108 patients (54.3%) suffer from dry eye syndrome. Although dry eye syndrome was more ...

It's a daycare procedure and doesn't require hospitalisation. However, it is an expensive treatment. Will my health insurance ...

Highlighting the event is the immersive simulation, “Seeing Beyond the Ordinary and Repairing Damages,” led by world-renowned ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

The implementation of AIDRSS offers transformative implications for DR screening in India, particularly in rural and ...

Diabetic retinopathy is a serious concern for people dealing with diabetes. Detecting diabetic retinopathy poses significant challenges, requiring skilled professionals, extensive manual image ...

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...

Insurance coverage for intravitreal injections, an essential treatment for diabetic retinopathy, depends on the specific terms and conditions of an individual’s health insurance policy.